PRIME: priority medicines scheme
PRIME is EMA's voluntary scheme of early, enhanced regulatory support for medicines in development that target an unmet medical need.
Also known as: PRIority MEdicines, PRIME scheme, EMA PRIME
3 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Run by
- The European Medicines Agency, since 2016
- Eligibility
- Same criteria as accelerated assessment: major public health interest, unmet medical need
- Decision
- Adopted by the CHMP within 40 days, after review by the SAWP
- Entry point
- Proof of concept; proof of principle for SMEs and academia
How it works
PRIME, short for priority medicines, was launched by the European Medicines Agency in 2016. It has no legal basis of its own. It builds on tools that already exist in Regulation (EC) No 726/2004, chiefly scientific advice and accelerated assessment under Article 14(9), and brings them forward in development. The scheme is limited to medicines that are not authorised in the EU and for which the developer intends an initial application through the centralised procedure. The eligibility criteria are the same as for accelerated assessment: the medicine must be of major interest for public health, in particular for therapeutic innovation, which in practice means it targets an unmet medical need or offers a major therapeutic advantage over existing treatments.
Any sponsor can apply in the exploratory clinical phase, with preliminary clinical evidence of the medicine's promise, known as proof of concept. Small and medium-sized enterprises and applicants from the academic sector can apply earlier, on compelling non-clinical data and first-in-human studies showing adequate exposure and tolerability, known as proof of principle; this gives Early Entry PRIME status, and further data are needed for full eligibility. Requests are submitted through EMA's IRIS platform to published deadlines. A reviewer from the Scientific Advice Working Party and an EMA scientific officer assess the request, with the Committee for Advanced Therapies involved for advanced therapies, and the CHMP adopts the outcome within 40 days. There is no appeal against a refusal.
Once a medicine is admitted, EMA appoints a PRIME scientific coordinator at once and a CHMP or CAT rapporteur a month later, well before the usual point seven months ahead of submission. A kick-off meeting with the rapporteur and experts follows three to four months after eligibility. The developer then has access to iterative scientific advice, with the option of involving health technology assessment bodies and patients, expedited follow-up advice, a regulatory roadmap with a development tracker, and a submission readiness meeting about a year before the application. EMA publishes the list of medicines granted eligibility and updates it monthly.
PRIME changes the support, not the standard. The evidence required for authorisation is the same, the potential for accelerated assessment is confirmed only when the application is made, and eligibility can be withdrawn if emerging data no longer meet the criteria. PRIME also carries no exclusivity or protection period of its own, unlike an orphan designation.
What goes wrong
Applying when the pivotal trial is already running, when EMA considers there is little scope left for enhanced support and refuses; a justification that argues novelty or commercial importance rather than unmet medical need and the size of the effect; a larger company applying on non-clinical data alone, a stage open only to SMEs and academia; treating admission as a promise of accelerated assessment or approval; and joining the scheme but not acting on the advice received.
Timing
Day 0
Review of the eligibility request starts after a published submission deadline.
Day 40
CHMP adopts the outcome, after review by the SAWP.
1 month later
CHMP or CAT rapporteur is appointed.
3 to 4 months later
Kick-off meeting with the rapporteur and experts.
1 year before submission
Submission readiness meeting.
At submission
Potential for accelerated assessment is confirmed.
Eligibility requests are submitted to deadlines EMA publishes for each year. The review runs through the Scientific Advice Working Party, which comments at Day 30, and the CHMP adopts the outcome at Day 40. After a positive outcome the rapporteur is appointed one month later and the kick-off meeting takes place three to four months after eligibility. The submission readiness meeting is held about one year before the marketing authorisation application, and accelerated assessment is confirmed when the application is made.
PRIME: common questions
Who can apply for PRIME, and when?
Any developer of a medicine not yet authorised in the EU can apply once it has preliminary clinical evidence, called proof of concept, usually from exploratory trials. SMEs and academic applicants can apply earlier, on compelling non-clinical data and first-in-human tolerability data. Medicines already in pivotal trials or close to submission are generally too advanced.
Does PRIME guarantee accelerated assessment?
No. EMA says developers of a PRIME medicine can expect to be eligible for accelerated assessment, but the potential is confirmed only at the time of the marketing authorisation application, and the CHMP can still revert to the standard timetable during the procedure. PRIME does not change the evidence needed for approval.
What is the difference between PRIME and accelerated assessment?
PRIME is support during development: early rapporteur appointment, a kick-off meeting and repeated scientific advice. Accelerated assessment is a shorter review of the finished application, 150 days instead of 210. The eligibility criteria are the same, and a medicine can have accelerated assessment without ever having been in PRIME.